Apoptosis, Cancer and Development Laboratory-Equipe labellisée 'La Ligue', LabEx DEVweCAN, Institut Convergence PLASCAN, Cancer Research Center of Lyon (CRCL), INSERM U1052-CNRS UMR5286, Université de Lyon, Centre Léon Bérard, Lyon, France.
Department of Translational Research and Innovation, Centre Leon Bérard, Laboratoire des Modèles Tumoraux (LMT) Fondation Synergie Lyon Cancer, Lyon, France.
Cancer Res. 2020 May 15;80(10):1970-1980. doi: 10.1158/0008-5472.CAN-19-1340. Epub 2020 Feb 14.
The Sonic Hedgehog (SHH) pathway plays a key role in cancer. Alterations of SHH canonical signaling, causally linked to tumor progression, have become rational targets for cancer therapy. However, Smoothened (SMO) inhibitors have failed to show clinical benefit in patients with cancers displaying SHH autocrine/paracrine expression. We reported earlier that the SHH receptor Patched (PTCH) is a dependence receptor that triggers apoptosis in the absence of SHH through a pathway that differs from the canonical one, thus generating a state of dependence on SHH for survival. Here, we propose a dual function for SHH: its binding to PTCH not only activates the SHH canonical pathway but also blocks PTCH-induced apoptosis. Eighty percent, 64%, and 8% of human colon, pancreatic, and lung cancer cells, respectively, overexpressed SHH at transcriptional and protein levels. In addition, SHH-overexpressing cells expressed all the effectors of the PTCH-induced apoptotic pathway. Although the canonical pathway remained unchanged, autocrine SHH interference in colon, pancreatic, and lung cell lines triggered cell death through PTCH proapoptotic signaling. , SHH interference in colon cancer cell lines decreased primary tumor growth and metastasis. Therefore, the antitumor effect associated to SHH deprivation, usually thought to be a consequence of the inactivation of the canonical SHH pathway, is, at least in part, because of the engagement of PTCH proapoptotic activity. Together, these data strongly suggest that therapeutic strategies based on the disruption of SHH/PTCH interaction in SHH-overexpressing cancers should be explored. SIGNIFICANCE: Sonic Hedgehog-overexpressing tumors express PTCH-induced cell death effectors, suggesting that this death signaling could be activated as an antitumor strategy.
Sonic Hedgehog (SHH) 通路在癌症中起着关键作用。SHH 经典信号通路的改变与肿瘤的进展有因果关系,已成为癌症治疗的合理靶点。然而,Smoothened (SMO) 抑制剂未能在显示 SHH 自分泌/旁分泌表达的癌症患者中显示临床获益。我们之前报道过,SHH 受体 Patched (PTCH) 是一种依赖受体,它通过与经典途径不同的途径在没有 SHH 的情况下触发细胞凋亡,从而产生对 SHH 生存的依赖状态。在这里,我们提出了 SHH 的双重功能:它与 PTCH 的结合不仅激活了 SHH 的经典途径,而且阻断了 PTCH 诱导的细胞凋亡。分别有 80%、64%和 8%的人结肠癌、胰腺癌和肺癌细胞在转录和蛋白水平上过度表达 SHH。此外,SHH 过表达细胞表达了 PTCH 诱导的凋亡途径的所有效应物。尽管经典途径保持不变,但在结肠、胰腺和肺癌细胞系中,自分泌 SHH 干扰通过 PTCH 促凋亡信号触发细胞死亡。在结肠癌细胞系中,SHH 干扰降低了原发肿瘤的生长和转移。因此,与 SHH 剥夺相关的抗肿瘤作用,通常被认为是经典 SHH 途径失活的结果,至少部分是因为激活了 PTCH 促凋亡活性。总之,这些数据强烈表明,应该探索基于破坏 SHH/PTCH 相互作用的治疗策略。意义:过度表达 Sonic Hedgehog 的肿瘤表达 PTCH 诱导的细胞死亡效应物,这表明这种死亡信号可以作为一种抗肿瘤策略被激活。